Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
VRTX Vertex Pharmaceuticals Incorporated
JOURNAVX is a non-opioid pain management therapy, aligning with the non-opioid pain management investable theme.
$107.99B
$421.35
+2.90%
VTRS Viatris Inc.
Pipeline includes non-opioid pain management options (e.g., fast-acting meloxicam) as growth drivers.
$11.86B
$10.17
+0.49%
AXSM Axsome Therapeutics, Inc.
Symbravo's non-opioid analgesic profile supports Non-Opioid Pain Management as a broader category.
$6.88B
$137.86
-0.21%
ATRC AtriCure, Inc.
Pain-management devices (cryoSPHERE family, cryoXT) provide non-opioid analgesia, a key product category.
$1.59B
$31.94
-0.34%
LXRX Lexicon Pharmaceuticals, Inc.
Pilavapadin is a non-opioid pain management therapy in development for neuropathic pain, constituting a non-opioid analgesic product category.
$516.03M
$1.42
+13.20%
ANIK Anika Therapeutics, Inc.
Non-opioid pain management solutions through HA injections address OA pain.
$145.19M
$10.05
+2.08%
SCLX Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
$127.56M
$18.51
-1.59%
ASRT Assertio Holdings, Inc.
INDOCIN, SPRIX, and CAMBIA represent non-opioid analgesics, supporting the Non-Opioid Pain Management theme.
$76.72M
$0.80
+5.26%
GRCE Grace Therapeutics, Inc.
GTx-101.00 is a non-narcotic topical analgesic in development for PHN, supporting the 'Non-Opioid Pain Management' theme.
$41.35M
$3.01
+0.67%
APUS Apimeds Pharmaceuticals US, Inc
Apitox functions as a non-opioid analgesic for pain management, aligning with the Non-Opioid Pain Management investable theme.
$31.09M
$2.69
+20.63%
CPIX Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
$29.62M
$1.99
-6.57%
MIRA MIRA Pharmaceuticals, Inc.
The company's pain therapies are non-opioid analgesics, placing them under 'Non-Opioid Pain Management'.
$24.70M
$1.47
+0.34%

Loading company comparison...

Loading research report...

VRTX Vertex Pharmaceuticals Incorporated

Vertex Reports Strong 48‑Week Data for Povetacicept in IgA Nephropathy and Primary Membranous Nephropathy

Nov 09, 2025
LXRX Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Beats Q3 2025 Earnings on Strong Licensing Revenue and Cost Controls

Nov 06, 2025
VTRS Viatris Inc.

Viatris Reports Q3 2025 Earnings: Revenue Declines 1‑2% YoY, EPS Beats Estimates, Guidance Raised

Nov 06, 2025
SCLX Scilex Holding Company

Scilex Secures Exclusive Tokenization License with Datavault AI to Expand Biotech Exchange Platform

Nov 04, 2025
VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Reports Q3 2025 Earnings, Raises Full‑Year Guidance

Nov 04, 2025
MIRA MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Ketamir‑2, Targets Chemotherapy‑Induced Neuropathic Pain

Oct 24, 2025
GRCE Grace Therapeutics, Inc.

Grace Therapeutics Raises $4.0 Million in Common Warrant Exercises Following FDA Acceptance of GTx‑104 NDA

Oct 23, 2025
CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Forms Joint Venture with RedHill Biopharma to Commercialize Talicia, a Leading H. pylori Therapy

Oct 20, 2025
MIRA MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals Announces Oral Mira‑55 Outperforms Injected Morphine in Pain and Inflammation Study, Supporting IND for Chronic Inflammatory Pain

Oct 16, 2025
CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Adds Vibativ to Premier Group Purchasing Agreement

Oct 13, 2025

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks